Kv1.3 blockers are also considered as a therapeutic target for the treatment of obesity, thus highlighting the potential use of ShK in treatment of obesity and insulin resistance [74]. This evidence concerns the gene KCNA3 and obesity due to melanocortin 4 receptor deficiency.